-
公开(公告)号：US11752208B2
公开(公告)日：2023-09-12
申请号：US16990954
申请日：2020-08-11
IPC分类号： A61K39/395 , A61K9/00 , A61K47/18 , A61K47/26 , C07K16/24
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/183 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US11707524B2
公开(公告)日：2023-07-25
申请号：US17198983
申请日：2021-03-11
IPC分类号： A61K39/395 , A61K9/00 , A61K47/26 , C07K16/24 , A61K9/19 , A61K47/02 , A61K47/12 , A61K39/00
CPC分类号： A61K39/39591 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/12 , A61K47/26 , C07K16/241 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20210121566A1
公开(公告)日：2021-04-29
申请号：US16943086
申请日：2020-07-30
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20200016268A1
公开(公告)日：2020-01-16
申请号：US16584399
申请日：2019-09-26
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20180296674A1
公开(公告)日：2018-10-18
申请号：US15548730
申请日：2016-02-02
IPC分类号： A61K39/395 , A61K9/08 , C07K16/24 , A61K47/32 , A61K47/26 , A61K47/12 , A61K47/02 , A61K9/00
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, and at least one component selected from the group consisting of: a polyvinylpyrrolidone (PVP) surfactant, an inositol sugar stabiliser, and a gluconate salt toncifier. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20230338527A1
公开(公告)日：2023-10-26
申请号：US17979309
申请日：2022-11-02
IPC分类号： A61K39/395 , A61K9/00 , A61K47/26 , A61K47/18 , C07K16/24
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/183 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US11752209B2
公开(公告)日：2023-09-12
申请号：US17979272
申请日：2022-11-02
IPC分类号： A61K39/395 , A61K9/00 , A61K47/18 , A61K47/26 , C07K16/24
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/183 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20230061801A1
公开(公告)日：2023-03-02
申请号：US17979272
申请日：2022-11-02
IPC分类号： A61K39/395 , A61K47/26 , C07K16/24 , A61K9/00 , A61K47/18
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20210322551A1
公开(公告)日：2021-10-21
申请号：US17348368
申请日：2021-06-15
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20210308262A1
公开(公告)日：2021-10-07
申请号：US17348078
申请日：2021-06-15
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.025 秒)
